Diabetic macular edema responds to treatment with ranibizumab (Lucentis, Genentech), according to results of the RESOLVE study. The patient responses to the drug in the changes in the visual acuity and central macular thickness were significantly better in the groups treated with two concentrations of ranibizumab compared with the sham-treated group.
A hydrophilic IOL (Afinity CQ2015, STAAR Surgical) seems to be a more efficient delivery system of moxifloxacin 0.5% (Vigamox, Alcon Laboratories) than a hydrophobic IOL (AcrySof SA60, Alcon Laboratories), according to the results of a comparison of lenses soaked in the antibiotic. Both lenses appear to be capable of delivering antibiotics to achieve clinically relevant levels, however.
E10030, ranibizumab have biologic activity against choroidal neovascularization in wet age-related macular degeneration, results show
In a phase I study, E10030 (Ophthotech) combined with ranibizumab (Lucentis, Genentech) in patients with subfoveal neovascular age-related macular degeneration was well tolerated and seemed to have biologic activity against choroidal neovascularization, according to one ophthalmologist.
When treating diabetic macular edema, focal/grid photocoagulation more effective than intravitreal triamcinolone, results show
Intravitreal triamcinolone (IVTA) for treating diabetic macular edema (DME) does not seem to be beneficial over the long term compared with focal/grid photocoagulation, and treatment with IVTA results in a higher chance of developing a cataract compared with treatment with the laser, according to a 3-year comparison study. Focal/grid photocoagulation, therefore, remains the most effective treatment for DME, according to one ophthalmologist.
Ophthalmologists who responded to questions about treatment of dry eye indicated that there are limitations in the available treatment options, especially for patients with moderate to severe cases of the disease, and that only 5% of ophthalmologists saw existing treatments as effective for the patients with the worst cases.
A new product (NutriDox Convenience Kit, Advanced Vision Research) is designed to make the treatment of meibomitis, posterior blepharitis, and meibomian gland disease more convenient for patients and clinicians. The prescription-only system includes an antibiotic, nutrition therapy, and a lid-cleansing component.
A careful look at all the clues can help the clinician differentiate between dry eye and allergies. The patient history may contain the most important clues for establishing a diagnosis.
Ecabet sodium (ISTA Pharmaceuticals), an anti-ulcer and gastritis drug under development for the treatment of dry eye, showed positive results in a phase IIb clinical trial of the drug.
Blink GelTears and Blink Tears Preservative-Free (Advanced Medical Optics) are two new over-the-counter products for the treatment of dry eye disease. These products are gaining in popularity with ophthalmologist because of the rapid long-lasting beneficial response they produce in this patient population and the absence of a preservative. The products are also beneficial for patients who have undergone LASIK and cataract surgery and develop subsequent dry eye signs and symptoms postoperatively.
A new surgical platform (Constellation Vision System, Alcon Laboratories) incorporates advanced design features for improved surgical efficiency and safety. Vitrectomy probes (Ultravit, Alcon) facilitate high-speed cutting and control of the duty cycle.